DocGo (DCGO) Q4 2025 earnings review
Guidance Raised and Strategic Alternatives Explored Amidst Massive Impairments
DocGo's fourth quarter was a noisy culmination of a heavy transition year. Headline revenue fell 38% YoY to $74.9M due to the planned sunset of migrant programs, but base revenue (ex-migrant) grew 11% YoY to $67.5M, Reversing three quarters of sequential top-line contraction. However, the bottom line suffered a sudden shock: a $142.3M net loss driven by $78M in non-cash impairments to goodwill and intangibles. Despite the ugly GAAP optics, management raised 2026 revenue and EBITDA guidance due to record base volumes and integration of SteadyMD. Simultaneously, the Board initiated a formal process to explore strategic alternatives, signaling a potential sale.
🐂 Bull Case
Excluding the volatile migrant contracts, the core business is Reversing its prior sluggishness. Q4 ex-migrant revenue grew 11% YoY, and the 'healthcare at any address' segment tripled YoY to $12.8M. 2026 guidance implies healthy, predictable growth.
Management significantly raised 2026 Adjusted EBITDA guidance from a loss of $15-$25M to a loss of just $5-$10M, projecting a return to outright profitability in the second half of 2026, driven by cost efficiency initiatives.
🐻 Bear Case
The $78M in non-cash impairments ($50M goodwill, $23M intangibles, $5M equity) is a massive red flag. It indicates that previous acquisitions or investments severely underperformed their modeled expectations, bringing management's capital allocation track record into question.
Cash and equivalents dropped from $95.2M at the end of Q3 to $68.3M by year-end. Management blamed delayed payments from outstanding migrant-related receivables, of which $20M remains uncollected.
⚖️ Verdict: ⚪
Neutral. The underlying base business is finally showing the growth management promised, and the raised guidance is a strong positive. However, the $78M impairment and delayed cash collections are severe enough to temper excitement until the strategic review yields tangible results.
Key Themes
Strategic Alternatives Process Initiated
In a major narrative shift, DocGo announced the initiation of a formal process to explore strategic alternatives to maximize shareholder value. This usually points to a potential sale of the company or taking it private. This announcement effectively puts a floor under the stock, as the market will price in an M&A premium, shifting focus away from near-term unprofitability toward enterprise valuation.
'Healthcare at Any Address' Triples
Combined revenues from the core strategic growth engine (care gap closure, transitions of care, remote patient monitoring, mobile phlebotomy, and virtual care) Accelerating rapidly, tripling YoY to $12.8M in Q4. Healthcare in the home visit volumes surged 113%, proving the pivot away from episodic municipal contracts is executing successfully.
Massive Write-Downs Destroy Capital Optically
The company absorbed $78M in non-cash impairments during Q4, including $50M in goodwill, $23M in intangibles, and a $5M equity investment write-down. This is a staggering amount for a company of DocGo's size, representing the erasure of significant premiums paid during prior M&A. This calls into question the diligence and valuation models used for historical acquisitions.
SteadyMD Integration and GLP-1 Demand
The recently acquired SteadyMD platform achieved its highest monthly revenue on record in February 2026. The company is actively expanding its clinical workforce to meet surging macro-level demand for virtual care related to branded GLP-1 weight loss treatments. This technological integration bridges the gap between physical last-mile transport and digital prescriptions.
Cash Position Pressured by Delayed Receivables
While management frequently highlighted balance sheet strength in prior quarters, total cash and equivalents dropped noticeably from $95.2M in 25Q3 to $68.3M in 25Q4. Management explicitly noted that cash collections were lower than expectations due to delayed payments from migrant-related receivables, contradicting the narrative that collections were running smoothly. Approximately $20M remains outstanding.
Medical Transportation Baseline Remains Stable
Despite the noise in the Mobile Health segment, the foundational Medical Transportation segment is Stable. Q4 2025 revenue was $50.2M, up slightly from $49.1M a year ago. Trip volumes increased 11% YoY in Q4, indicating the company is successfully hiring EMS staff to fill existing demand.
Other KPIs
Decelerating sharply from $1.1M in Q4 2024. The loss widened despite the base revenue growth, primarily due to the severe margin discrepancy between the high-margin winding-down migrant contracts and the early-stage investments required to scale the new payer/provider business.
Down heavily from $71.8M a year ago due to the loss of $52.8M in YoY migrant revenue. However, excluding those migrant programs, Mobile Health revenue actually increased 47% YoY, aided by the October 2025 acquisition of SteadyMD.
Accelerating. Up from 1.3 million last quarter and 1.2 million in Q2. This metric acts as a leading indicator of future primary care and in-home visits.
Guidance
Reversing. Though lower than the $322.2M generated in FY25, the FY26 guide contains zero migrant revenue (compared to $69.6M in FY25). This means the core business is expected to grow organically by roughly 15-23%. The guidance was raised from a prior outlook of $280-$300 million.
Accelerating aggressively. Management dramatically raised the outlook from a previous expected loss of $15-$25 million. The majority of the loss is expected in 1H26, with an expectation to cross into profitability in 2H26. This relies heavily on full-year impacts of corporate efficiency initiatives and the scaling of SteadyMD.
Key Questions
Trigger for Strategic Alternatives
With the base business accelerating and EBITDA guidance raised significantly, what was the primary catalyst for exploring strategic alternatives now, rather than waiting for the transition to show up in the bottom line in 2H26?
Details on the Impairment Charge
Can you provide specific detail on which previous acquisitions or assets triggered the $78M in goodwill and intangible impairments? How does this alter your approach to future tuck-in M&A?
Migrant Receivable Timeline
You noted a delay in cash collections for the final $20M in migrant receivables. What is the explicit timeline for this collection, and are there any disputes with municipal clients regarding these invoices?
GLP-1 Economics
You mentioned expanding the clinical workforce to meet GLP-1 demand via SteadyMD. What are the unit economics and margin profiles of this specific virtual care offering compared to your traditional in-home visits?